Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityActive in the last 2 years

Lei Huang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4225-9200; OpenAlex author ID A5032285655. Sources: OpenAlex.

Their work

Papers
14
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2018: 2 papers · 2019: 2 papers · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 3 papers · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 14

  1. Coixenolide Enhances Antitumor Immunity of Cytotoxic CD8+ T Cells by Inhibiting S100A8/A9-CD36 Axis in Obesity-Associated Pancreatic Adenocarcinoma. Co-author DOI 10.1002/advs.202515759↗
  2. Global, regional, and national burdens of pancreatic cancer and pancreatitis among older adults from 1990 to 2021: A comparative investigation. Co-author DOI 10.1016/j.pan.2026.07.012↗
  3. Development and Validation of the Predictive and Prognostic ChemoResist Signature in Resected Pancreatic Ductal Adenocarcinoma: Multicohort Study. Co-author DOI 10.1097/sla.0000000000006610↗
  4. Corrections to: “The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super‐enhancer activity and the PI3K/AKT/mTOR signall… Co-author DOI 10.1002/ctm2.70158↗
  5. High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospect… Co-author DOI 10.1186/s12967-024-04989-z↗
  6. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic… Co-author DOI 10.1002/ctm2.1500↗
  7. Acute toxicities of intravenous, intraperitoneal, or intratumoral injection of natural killer cells in human pancreatic adenocarcinoma-bearing mice: Randomized… Co-author DOI 10.1016/j.intimp.2023.110881↗
  8. Gene signature developed for predicting early relapse and survival in early-stage pancreatic cancer. Co-author DOI 10.1093/bjsopen/zrad031↗
  9. S-1 Maintenance Therapy After First-Line Treatment With Nab-Paclitaxel Plus S-1 for Advanced Pancreatic Adenocarcinoma: A Real-World Study. Co-author DOI 10.3389/fonc.2022.865404↗
  10. Significance of Examined Lymph Node Number in Accurate Staging and Long-term Survival in Resected Stage I-II Pancreatic Cancer-More is Better? A Large Internat… Co-author DOI 10.1097/sla.0000000000003558↗
  11. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Co-author DOI 10.1136/gutjnl-2017-314828↗
  12. Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a … Co-author DOI 10.1186/s12916-019-1304-y↗
  13. Nonsurgical therapies for resected and unresected pancreatic cancer in Europe and USA in 2003-2014: a large international population-based study. Co-author DOI 10.1002/ijc.31628↗
  14. Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international populati… Co-author DOI 10.1186/s12916-018-1120-9↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Guanghai Dai · 6 shared papers, 2022–2025 · strength 1.26
  2. Yan Xia Shi · 5 shared papers, 2022–2025 · strength 1.05
  3. Mancang Gu · 4 shared papers, 2023–2026 · strength 0.86
  4. Quanli Han · 4 shared papers, 2022–2025 · strength 0.84
  5. Kaidi Chen · 3 shared papers, 2023–2026 · strength 0.65
  6. Shasha Guan · 3 shared papers, 2022–2024 · strength 0.54
  7. Liangchao Zhao · 2 shared papers, 2023–2025 · strength 0.47
  8. Lina Jansen · 5 shared papers, 2018–2021 · strength 0.40
  9. V.E.P.P. Lemmens · 5 shared papers, 2018–2021 · strength 0.40
  10. Lydia G. van der Geest · 5 shared papers, 2018–2021 · strength 0.40
  11. Hermann Brenner · 5 shared papers, 2018–2021 · strength 0.40
  12. Zhaoshen Li · 1 shared paper, 2026 · strength 0.36
  13. Wen‐Bin Zou · 1 shared paper, 2026 · strength 0.36
  14. Zhuan Liao · 1 shared paper, 2026 · strength 0.36
  15. Marc G. Besselink · 4 shared papers, 2018–2021 · strength 0.33
  16. Robert Grützmann · 3 shared papers, 2019–2021 · strength 0.26
  17. Rong Chen · 1 shared paper, 2026 · strength 0.22
  18. Yuwei Qi · 1 shared paper, 2026 · strength 0.22
  19. Yan Shi · 1 shared paper, 2023 · strength 0.22
  20. Yan Shi · 1 shared paper, 2024 · strength 0.22
  21. Jie Li · 1 shared paper, 2022 · strength 0.15
  22. Bas Groot Koerkamp · 1 shared paper, 2021 · strength 0.12
  23. Hjalmar C. van Santvoort · 1 shared paper, 2021 · strength 0.12
  24. Esther Molina‐Montes · 1 shared paper, 2019 · strength 0.06
  25. Markus Wolfgang Büchler · 1 shared paper, 2019 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.